AAAAAA
Results:
1-11
|
Results: 11
Authors:
FARKER K
LEHMANN MH
KASTNER R
HOFFMANN A
JANITZKY V
SCHUBERT J
MATZ U
HOFMANN W
Citation: K. Farker et al., CYP2E1 GENOTYPING IN RENAL-CELL UROTHELIAL CANCER-PATIENTS IN COMPARISON WITH CONTROL POPULATIONS, International journal of clinical pharmacology and therapeutics, 36(9), 1998, pp. 463-468
Authors:
FARKER K
LEHMANN MH
OELSCHLAGEL B
HAERTING J
HOFFMANN A
JANITZKY V
SCHUBERT J
Citation: K. Farker et al., IMPACT OF CYP2E1 GENOTYPE IN RENAL-CELL AND UROTHELIAL CANCER-PATIENTS, Experimental and toxicologic pathology, 50(4-6), 1998, pp. 425-431
Authors:
HOFFMANN H
DITTGEN M
HOFFMANN A
BARTSCH C
BREITBARTH H
TIMPE C
FARKER K
SCHMIDT U
MELLINGER U
ZIMMERMANN H
GRASER T
OETTEL M
Citation: H. Hoffmann et al., EVALUATION OF AN ORAL PULSATILE DELIVERY SYSTEM FOR MELATONIN IN HUMANS, Die Pharmazie, 53(7), 1998, pp. 462-466
Authors:
REINHARDT D
SIGUSCH HH
VOGT SF
FARKER K
MULLER S
HOFFMANN A
Citation: D. Reinhardt et al., ABSENCE OF ASSOCIATION BETWEEN A COMMON MUTATION IN THE METHYLENETETRAHYDROFOLATE REDUCTASE GENE AND THE RISK OF CORONARY-ARTERY DISEASE, European journal of clinical investigation, 28(1), 1998, pp. 20-23
Authors:
NASSR N
FARKER K
LAUTENSCHLAGER M
NAGEL U
ZIMMERMANN H
MELLINGER U
HOFFMANN A
Citation: N. Nassr et al., BIOAVAILABILITY STUDY WITH 2 DIFFERENT LEVONORGESTREL-CONTAINING DRUGS IN WOMEN, International journal of clinical pharmacology and therapeutics, 35(3), 1997, pp. 123-127
Authors:
FARKER K
SCHWEER H
VOLLANDT R
NASSR N
NAGEL U
SEYBERTH HW
HOFFMANN A
OETTEL M
Citation: K. Farker et al., MEASUREMENTS OF URINARY PROSTAGLANDINS IN YOUNG OVULATORY WOMEN DURING THE MENSTRUAL-CYCLE AND IN POSTMENOPAUSAL WOMEN, Prostaglandins, 54(3), 1997, pp. 655-664
Authors:
SIGUSCH HH
VOGT S
GRUBER U
REINHARDT D
LANG K
SURBER R
FARKER K
MULLER S
HOFFMANN A
Citation: Hh. Sigusch et al., ANGIOTENSIN-I-CONVERTING ENZYME DD GENOTYPE IS A RISK FACTOR OF CORONARY-ARTERY DISEASE, Scandinavian journal of clinical & laboratory investigation, 57(2), 1997, pp. 127-132
Authors:
FARKER K
NASSR N
HUCK F
ZERLE G
ROSENKRANZ B
SCHMIEDER G
HOFFMANN A
Citation: K. Farker et al., DIPYRONE AND DICLOFENAC DO NOT INFLUENCE CREATININE-CLEARANCE, INULIN-CLEARANCE OR PAH-CLEARANCE IN HEALTHY MALE-VOLUNTEERS, International journal of clinical pharmacology and therapeutics, 33(3), 1995, pp. 125-130
Authors:
FARKER K
HENSCHEL L
MARSCHNER JP
REIMANN I
VOLKMANN H
HOFFMANN A
Citation: K. Farker et al., PHARMACOKINETICS OF THE NEW ANTIARRHYTHMI C AGENT Z-2-AMINO-5-CHLOROBENZOPHENONEAMIDINOHYDRAZONE ACETATE (AWD-G256), Die Pharmazie, 48(5), 1993, pp. 373-380
Authors:
VOLKMANN H
HOFFMANN A
KUHNERT H
DANNBERG G
HEINKE M
REIMANN I
MARSCHNER JP
FARKER K
Citation: H. Volkmann et al., CLINICAL-ELECTROPHYSIOLOGICAL STUDIES ON THE EFFECT OF THE ANTIARRHYTHMIC DRUG AWD-G256 IN MAN, Die Pharmazie, 48(5), 1993, pp. 380-385
Authors:
VOLKMANN H
DANNBERG G
KUHNERT H
HOFFMANN A
MARSCHNER JP
REIMANN I
FARKER K
Citation: H. Volkmann et al., HEMODYNAMIC-EFFECTS AND ADVERSE-EFFECTS O F THE ANTIARRHYTHMIC DRUG AWD-G256 IN MAN, Die Pharmazie, 48(5), 1993, pp. 385-387
Risultati:
1-11
|